Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 6/2018

04.06.2018 | Review

A global perspective on vasoactive agents in shock

verfasst von: Djillali Annane, Lamia Ouanes-Besbes, Daniel de Backer, Bin DU, Anthony C. Gordon, Glenn Hernández, Keith M. Olsen, Tiffany M. Osborn, Sandra Peake, James A. Russell, Sergio Zanotti Cavazzoni

Erschienen in: Intensive Care Medicine | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We set out to summarize the current knowledge on vasoactive drugs and their use in the management of shock to inform physicians’ practices.

Methods

This is a narrative review by a multidisciplinary, multinational—from six continents—panel of experts including physicians, a pharmacist, trialists, and scientists.

Results and conclusions

Vasoactive drugs are an essential part of shock management. Catecholamines are the most commonly used vasoactive agents in the intensive care unit, and among them norepinephrine is the first-line therapy in most clinical conditions. Inotropes are indicated when myocardial function is depressed and dobutamine remains the first-line therapy. Vasoactive drugs have a narrow therapeutic spectrum and expose the patients to potentially lethal complications. Thus, these agents require precise therapeutic targets, close monitoring with titration to the minimal efficacious dose and should be weaned as promptly as possible. Moreover, the use of vasoactive drugs in shock requires an individualized approach. Vasopressin and possibly angiotensin II may be useful owing to their norepinephrine-sparing effects.
Literatur
1.
Goodman and Gilman’s (2011) Pharmacological Basis of Therapeutics Twelfth (ed). New York
2.
Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for the management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377PubMedCrossRef
3.
Aguilera G, Rabadan-Diehl C (2000) Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 96(1–2):23–29PubMedCrossRef
4.
Yamamoto K, Ikeda U, Okada K et al (1997) Arginine vasopressin increases nitric oxide synthesis in cytokine-stimulated rat cardiac myocytes. Hypertension 30(5):1112–1120PubMedCrossRef
5.
Rudichenko VM, Beierwaltes WH (1995) Arginine vasopressin-induced renal vasodilation mediated by nitric oxide. J Vasc Res 32(2):100–105PubMedCrossRef
6.
Landry DW, Levin HR, Gallant EM et al (1997) Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95(5):1122–1125PubMedCrossRef
7.
Landry DW, Levin HR, Gallant EM et al (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 25(8):1279–1282PubMedCrossRef
8.
Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27(8):1416–1421PubMedCrossRef
9.
Malay MB, Ashton RC Jr, Landry DW, Townsend RN (1999) Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 47(4):699–703PubMedCrossRef
10.
Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96(3):576–582PubMedCrossRef
11.
Siami S, Polito A, Porcher R et al (2013) Thirst perception and osmoregulation of vasopressin secretion are altered during recovery from septic shock. PLoS One 8(11):e80190PubMedPubMedCentralCrossRef
12.
Boucheix OB, Milano SP, Henriksson M, Reinheimer TM (2013) Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs. Shock 39(6):533–538PubMedCrossRef
13.
Asfar P, Russell JA, Tuckermann J, Radermacher P (2016) Selepressin in septic shock: a step toward decatecholaminization? Crit Care Med 44(1):234–236PubMedCrossRef
14.
Russell JA, Vincent JL, Kjolbye AL et al (2017) Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care 21(1):213PubMedPubMedCentralCrossRef
15.
He X, Su F, Taccone FS, Laporte R et al (2016) A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med 44(1):23–31PubMedCrossRef
16.
Maybauer MO, Maybauer DM, Enkhbaatar P et al (2014) The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med 42(7):e525–e533PubMedPubMedCentralCrossRef
17.
Farmakis D, Alvarez J, Gal TB et al (2016) Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol 222:303–312PubMedCrossRef
18.
19.
Boldt J, Menges T, Kuhn D, Diridis C, Hempelmann G (1995) Alterations in circulating vasoactive substances in the critically ill–a comparison between survivors and non-survivors. Intensive Care Med 21(3):218–225PubMedCrossRef
20.
21.
Reynolds RD, Gorczynski RJ, Quon CY (1986) Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol 26(suppl A):A3–A14PubMedCrossRef
22.
Atarashi H, Kuruma A, Yashima M et al (2000) Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther 68(2):143–150PubMedCrossRef
23.
Page IH, Helmer OM (1940) A crystalline pressor substance (Angiotonin) resulting form the reaction between renin and renin-activator. J Exp Med 71(1):29–42PubMedPubMedCentralCrossRef
24.
Rajagopalan S, Kurz S, Münzel T et al (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97(8):1916–1923PubMedPubMedCentralCrossRef
25.
Khanna A, English SW, Wang XS et al (2017) Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377:419–430PubMedCrossRef
26.
27.
Perez P, Kimmoun A, Blime V, Levy B (2014) Increasing mean arterial pressure in cardiogenic shock secondary to myocardial infarction: effects on hemodynamics and tissue oxygenation. Shock 41(4):269–274PubMedCrossRef
28.
Maas JJ, Pinsky MR, de Wilde RB, de Jonge E, Jansen JR (2013) Cardiac output response to norepinephrine in postoperative cardiac surgery patients: interpretation with venous return and cardiac function curves. Crit Care Med 41(1):143–150PubMedCrossRef
29.
Levy B, Perez P, Perny J, Thivilier C, Gerard A (2011) Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 39(3):450–455PubMedCrossRef
30.
Guinot PG, Longrois D, Kamel S, Lorne E, Dupont H (2018) Ventriculo-arterial coupling analysis predicts the hemodynamic response to norepinephrine in hypotensive postoperative patients: a prospective observational study. Crit Care Med 46(1):e17–e25PubMedCrossRef
31.
Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F (2008) Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med. 36(6):1701–1706PubMedCrossRef
32.
Sun D, Huang A, Mital S et al (2002) Norepinephrine elicits beta2-receptor-mediated dilation of isolated human coronary arterioles. Circulation 106(5):550–555PubMedCrossRef
33.
Annane D, Vignon P, Renault A et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370(9588):676–684PubMedCrossRef
34.
Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J, CAT Study investigators (2008) A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34(12):2226–2234PubMedCrossRef
35.
Marik PE, Mohedin M (1994) The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 272(17):1354–1357PubMedCrossRef
36.
van Diepen S, Katz JN, Albert NM et al (2017) Contemporary management of cardiogenic shock: a scientific statement from the American heart association. Circulation 136(16):e232–e268PubMedCrossRef
37.
Mon W, Stewart A, Fernando R et al (2017) Cardiac output changes with phenylephrine and ephedrine infusions during spinal anesthesia for cesarean section: a randomized, double-blind trial. J Clin Anesth 37:43–48PubMedCrossRef
38.
39.
Bouferrache K, Amiel JB, Chimot L et al (2012) Initial resuscitation guided by the surviving sepsis campaign recommendations and early echocardiographic assessment of hemodynamics in intensive care unit septic patients: a pilot study. Crit Care Med 40(10):2821–2827PubMedCrossRef
40.
Schumann J, Henrich EC, Strobl H et al. (2018) Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database of Systematic Reviews. Issue 1, Art. No.: CD009669
41.
Morelli A, Ertmer C, Westphal M et al (2013) Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 310(16):1683–1691PubMedCrossRef
42.
Aviado DM Jr, Schmidt CF (1957) Effects of sympathomimetic drugs on pulmonary circulation: with special reference to a new pulmonary vasodilator. J Pharmacol Exp Ther 120(4):512–527PubMed
43.
Monnet X, Jabot J, Maizel J, Richard C, Teboul JL (2011) Norepinephrine increases cardiac preload and reduces preload dependency assessed by passive leg raising in septic shock patients. Crit Care Med 39(4):689–694PubMedCrossRef
44.
Persichini R, Silva S, Teboul JL et al (2012) Effects of norepinephrine on mean systemic pressure and venous return in human septic shock. Crit Care Med 40(12):3146–3153PubMedCrossRef
45.
Hajjar LA, Vincent JL, Barbosa Gomes Galas FR et al (2017) Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the vancs randomized controlled trial. Anesthesiology 126(1):85–93PubMedCrossRef
46.
James A, Amour J (2018) Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: a discussion of the level of evidence. Anesthesiology 128(1):228PubMedCrossRef
47.
Cheng Y, Pan T, Ge M, et al. (2018) Evaluation of vasopressin for vasoplegic shock in patients with preoperative left ventricular dysfunction after cardiac surgery: a propensity-score analysis. Shock. Feb 7. 10.1097/shk.0000000000001114
48.
Lewis RJ, Angus DC, Laterre PF et al (2018) Rationale and design of an adaptive phase 2b/3 clinical trial of selepressin for adults in septic shock, Selepressin evaluation program for sepsis-induced shock-adaptive clinical trial. Ann Am Thorac Soc 15(2):250–257PubMedCrossRef
49.
Gordon AC, Perkins GD, Singer M et al (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375(17):1638–1648PubMedCrossRef
50.
De Backer D, Creteur J, Noordally O, Smail N, Gulbis B, Vincent JL (1998) Does hepato-splanchnic V O2/D O2 dependency exist in critically ill septic patients? Am J Respir Crit Care Med 157:1219–1225PubMedCrossRef
51.
Hernandez G, Bruhn A, Luengo C et al (2013) Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: a randomized, placebo-controlled, double-blind, crossover study. Intensive Care Med 39:1435–1443PubMedCrossRef
52.
De Backer D, Creteur J, Silva E, Vincent JL (2003) Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 31:1659–1667PubMedCrossRef
53.
van Haren FM, Rozendaal FW, van der Hoeven JG (2003) The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 124:2256–2260PubMedCrossRef
54.
Georger JF, Hamzaoui O, Chaari A, Maizel J, Richard C, Teboul JL (2010) Restoring arterial pressure with norepinephrine improves muscle tissue oxygenation assessed by near-infrared spectroscopy in severely hypotensive septic patients. Intensive Care Med 36:1882–1889PubMedCrossRef
55.
Boerma EC, Ince C (2010) The role of vasoactive agents in the resuscitation of microvascular perfusion and tissue oxygenation in critically ill patients. Intensive Care Med 36:2004–2018PubMedPubMedCentralCrossRef
56.
Jhanji S, Stirling S, Patel N, Hinds CJ, Pearse RM (2009) The effect of increasing doses of norepinephrine on tissue oxygenation and microvascular flow in patients with septic shock. Crit Care Med 37:1961–1966PubMedCrossRef
57.
Dubin A, Pozo MO, Casabella CA et al (2009) Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study. Crit Care 13:R92PubMedPubMedCentralCrossRef
58.
59.
Morelli A, Ertmer C, Rehberg S et al (2008) Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care 12:R143PubMedPubMedCentralCrossRef
60.
Morelli A, Lange M, Ertmer C et al (2008) Short-term effects of phenylephrine on systemic and regional hemodynamics in patients with septic shock: a crossover pilot study. Shock 29:446–451PubMedCrossRef
61.
Dubois MJ, De Backer D, Creteur J, Anane S, Vincent JL (2003) Effect of vasopressin on sublingual microcirculation in a patient with distributive shock. Intensive Care Med 29:1020–1023PubMedCrossRef
62.
Nygren A, Thoren A, Ricksten SE (2009) Vasopressin decreases intestinal mucosal perfusion: a clinical study on cardiac surgery patients in vasodilatory shock. Acta Anaesthesiol Scand 53:581–588PubMedCrossRef
63.
Boerma EC, van der Voort PHJ, Ince C (2005) Sublingual microcirculatory flow is impaired by the vasopressin- analogue terlipressin in a patient with catecholamine-resistant septic shock. Acta Anaesthesiol Scand 49:1387–1390PubMedCrossRef
64.
Asfar P, Bracht H, Radermacher P (2008) Impact of vasopressin analogues on the gut mucosal microcirculation. Best Pract Res Clin Anaesthesiol 22:351–358PubMedCrossRef
65.
Morelli A, Donati A, Ertmer C et al (2011) Short-term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock. Intensive Care Med 37:963–969PubMedCrossRef
66.
Morelli A, Donati A, Ertmer C et al (2011) Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock. Crit Care 15:R217PubMedPubMedCentralCrossRef
67.
Qiu X, Huang Y, Xu J, Qiu H, Yang Y (2014) Effects of terlipressin on microcirculation of small bowel mesentery in rats with endotoxic shock. J Surg Res 188:503–509PubMedCrossRef
68.
De Backer D, Creteur J, Dubois MJ et al (2006) The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med 34:403–408PubMedCrossRef
69.
Enrico C, Kanoore Edul VS et al (2012) Systemic and microcirculatory effects of dobutamine in patients with septic shock. J Crit Care 27:630–638PubMedCrossRef
70.
Ospina-Tascón GA, García Marin AF, Echeverri GJ et al (1985) Effects of dobutamine on intestinal microvascular blood flow heterogeneity and O2 extraction during septic shock. J Appl Physiol 122:1406–1417CrossRef
71.
Dubin A, Murias G, Sottile JP et al (2007) Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 33:485–494PubMedCrossRef
72.
Morelli A, Donati A, Ertmer C et al (2010) Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care 14:R232PubMedPubMedCentralCrossRef
73.
Fuchs C, Ertmer C, Rehberg S (2016) Effects of vasodilators on haemodynamic coherence. Best Pract Res Clin Anaesthesiol 30:479–489PubMedCrossRef
74.
Webber J, MacDonald A (1993) Metabolic actions of catecholamines in man. Baillière’s Clin Endocrinol Metab 7:393–413CrossRef
75.
Van den Berghe G, de Zegher F (1996) Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 24(9):1580–1590PubMedCrossRef
76.
Sharshar T, Annane D (2008) Endocrine effects of vasopressin in critically ill patients. Best Pract Res Clin Anesthesiol 22:265–273CrossRef
77.
Bermejo-Martin JF, Andaluz-Ojeda D, Almansa R et al (2016) Defining immunological dysfunction in sepsis: a requisite tool for precision medicine. J Infect 72(5):525–536PubMedCrossRef
78.
Parissis JT, Adamopoulos S, Antoniades C et al (2004) Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 93(10):1309–1312PubMedCrossRef
79.
Russell JA, Fjell C, Hsu JL et al (2013) Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock. Am J Resp Crit Care Med 188(3):356–364PubMedCrossRef
80.
Russell JA, Walley KR (2010) Vasopressin and its immune effects in septic shock. J Innate Immun 2(5):446–460PubMedCrossRef
81.
Gamper G, Havel C, Arrich J et al (2016) Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2:CD003709PubMed
82.
Gordon AC, Mason AJ, Thirunavukkarusu N et al (2016) Effect of early vasopressin vs norephinephrine on kidney failure patients with septic shock. The Vanish randomised clinical trial. JAMA 316(5):509–518PubMedCrossRef
83.
Russell JA, Walley KR, Singer J et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887PubMedCrossRef
84.
Russell JA, Walley KR, Gordon AC et al (2009) Interaction of vasopressin infusion, corticosteroid treatment and mortality of septic shock. Crit Care Med 37(3):811–818PubMedCrossRef
85.
De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789PubMedCrossRef
86.
Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H (2017) Association Between US norepinephrine shortage and mortality among patients with septic shock. JAMA 317(14):1433–1442PubMedCrossRef
87.
Belletti A, Benedetto U, Biondi-Zoccai G et al (2017) The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials. J Crit Care 37:91–98PubMedCrossRef
88.
Mehaffey JH, Johnston LE, Hawkins RB et al (2017) Methylene blue for vasoplegic syndrome after cardiac operation: early administration improves survival. Ann Thorac Surg 104:36–41PubMedCrossRefPubMedCentral
89.
Elkayam U, Tasissa G, Binanay C et al (2007) Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 153(1):98–104PubMedCrossRef
90.
91.
Aranda JM Jr, Schofield RB, Pauly DF et al (2003) Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 145(2):324–329PubMedCrossRef
92.
Harris T, Davenport R, Mak M, Brohi K (2018) The evolving science of trauma resuscitation. Emerg Med Clin North Am 36(1):85–106PubMedCrossRef
93.
94.
Rossaint R, Bouillon B, Cerny V et al (2016) The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 20:100PubMedPubMedCentralCrossRef
95.
Bayram B, Hocaoglu N, Atilla R, Kalkan S et al (2012) Effects of terlipressin in a rat model of severe uncontrolled hemorrhage via liver injury. Am J Emerg Med 30(7):1176–1182PubMedCrossRef
96.
Cohn SM, McCarthy J, Stewart RM et al (2011) Impact of low-dose vasopressin on trauma outcome: prospective randomized study. World J Surg 35(2):430–439PubMedCrossRef
97.
Westermann I, Dunser MW, Haas T et al (2007) Endogenous vasopressin and copeptin response in multiple trauma patients. Shock 28(6):644–649PubMed
98.
99.
Plurad DS, Talving P, Lam L et al (2011) Early vasopressor use in critical injury is associated with mortality independent from volume status. J Trauma 71(3):565–570 [discussion 570–572] PubMedCrossRef
100.
Sperry JL, Minei JP, Frankel HL (2008) Early use of vasopressors after injury: caution before constriction. J Trauma 64(1):9–14PubMedCrossRef
101.
Ponikowski P, Voors AA, Anker SD et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37(27):2129–2200PubMedCrossRef
102.
Excellence NIfHaC (2016) Sepsis : recognition, assessment and early management. In: sepsis: recognition, Assessment and early management. London.
103.
Vieillard-Baron A, Caille V, Charron C, Belliard G, Page B, Jardin F (2008) Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 36(6):1701–1706PubMedCrossRef
104.
Hollenberg SM (2009) Inotrope and vasopressor therapy of septic shock. Crit Care Clin 25(4):781–802 [ix] PubMedCrossRef
105.
LeDoux D, Astiz ME, Carpati CM, Rackow EC (2000) Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 28:2729–2732PubMedCrossRef
106.
Bourgoin A, Leone M, Delmas A, Garnier F, Albanese J, Martin C (2005) Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 33:780–786PubMedCrossRef
107.
Asfar P, Meziani F, Hamel JF et al (2014) High versus low blood-pressure targets in patients with septic shock. N Engl J Med 370:1583–1593PubMedCrossRef
108.
Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D (1994) Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 330(24):1717–1722PubMedCrossRef
109.
Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA, Emergency Medicine Shock Research Network (EMShockNet) Investigators (2010) Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 303(8):739–746PubMedPubMedCentralCrossRef
110.
Jansen TC, van Bommel J, Schoonderbeek FJ et al (2010) LACTATE study group: early lactate-guided therapy in intensive care unit patients: A multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med 182:752–761PubMedCrossRef
111.
Teboul JL, Saugel B, Cecconi M et al (2016) Less invasive hemodynamic monitoring in critically ill patients. Intensive Care Med 42:1350–1359PubMedCrossRef
112.
Cecconi M, De Backer D, Antonelli M et al (2014) Consensus on circulatory shock and hemodynamic monitoring. task force of the European society of intensive care medicine. Intensive Care Med 40:1795–1815PubMedPubMedCentralCrossRef
113.
Merouani M, Guignard B, Vincent F et al (2008) Norepinephrine weaning in septic shock patients by closed loop control based on fuzzy logic. Crit Care 12:R155PubMedPubMedCentralCrossRef
114.
Hammond DA, McCain K, Painter JT et al (2017) Discontinuation of vasopressin before norepinephrine in the recovery phase of septic shock. J Intensive Care Med 2017:885066617714209
115.
Bissell BD, Magee C, Moran P, Bastin MLT, Flannery AH (2017) Hemodynamic instability secondary to vasopressin withdrawal in septic shock. J Intensive Care Med 2017:885066617716396
116.
Annane D, Sébille V, Duboc D et al (1998) Incidence and prognosis of sustained arrhythmias in critically ill patients. Am J Respir Crit Care Med 178(1):20–25CrossRef
117.
Kido K, Guglin M (2017) Drug-induced takotsubo cardiomyopathy. J Cardiovasc Pharmacol Ther 22(6):552–563PubMedCrossRef
Metadaten
Titel
A global perspective on vasoactive agents in shock
verfasst von
Djillali Annane
Lamia Ouanes-Besbes
Daniel de Backer
Bin DU
Anthony C. Gordon
Glenn Hernández
Keith M. Olsen
Tiffany M. Osborn
Sandra Peake
James A. Russell
Sergio Zanotti Cavazzoni
Publikationsdatum
04.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 6/2018
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-018-5242-5

Weitere Artikel der Ausgabe 6/2018

Intensive Care Medicine 6/2018 Zur Ausgabe

Letter

Estimated cerebral perfusion pressure among post-cardiac arrest survivors

Correspondence

Paediatric sequential organ failure assessment score (pSOFA): a plea for the world-wide collaboration for consensus

Letter

Effect of a 24-h extended visiting policy on delirium in critically ill patients

Review

The present and future of cardiac arrest care: international experts reach out to caregivers and healthcare authorities

Review

Perioperative myocardial injury and the contribution of hypotension

What's New in Intensive Care

Does this patient have takotsubo syndrome?

Neu im Fachgebiet AINS

11.04.2024 | Rückenschmerzen | Nachrichten

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet

04.04.2024 | DGP 2024 | Kongressbericht | Nachrichten

Neue NIV-Leitlinie mit Anleitung zur Beatmungseinstellung vorgestellt
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren